JP2018514593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514593A5 JP2018514593A5 JP2018509731A JP2018509731A JP2018514593A5 JP 2018514593 A5 JP2018514593 A5 JP 2018514593A5 JP 2018509731 A JP2018509731 A JP 2018509731A JP 2018509731 A JP2018509731 A JP 2018509731A JP 2018514593 A5 JP2018514593 A5 JP 2018514593A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- cancer
- rad1901
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 5
- SIFNOOUKXBRGGB-AREMUKBSSA-N (6r)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound C1=CC(CCNCC)=CC=C1CN(CC)C1=CC(OC)=CC=C1[C@H]1CC2=CC=C(O)C=C2CC1 SIFNOOUKXBRGGB-AREMUKBSSA-N 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 108010007005 Estrogen Receptor alpha Proteins 0.000 claims 3
- 102100038595 Estrogen receptor Human genes 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 229940046836 anti-estrogen Drugs 0.000 claims 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims 2
- 239000003886 aromatase inhibitor Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000328 estrogen antagonist Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- XGFHYCAZOCBCRQ-FBHGDYMESA-N (6r)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol;dihydrochloride Chemical group Cl.Cl.C1=CC(CCNCC)=CC=C1CN(CC)C1=CC(OC)=CC=C1[C@H]1CC2=CC=C(O)C=C2CC1 XGFHYCAZOCBCRQ-FBHGDYMESA-N 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical group O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 229940087620 aromasin Drugs 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 201000002511 pituitary cancer Diseases 0.000 claims 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- MWMXLLVOFFIXAS-JUERFOTFSA-N CCNCCc1ccc(CN(CC)c2c([C@H](CC3)CC4C3=CC(O)=CC4)ccc(OC)c2)cc1 Chemical compound CCNCCc1ccc(CN(CC)c2c([C@H](CC3)CC4C3=CC(O)=CC4)ccc(OC)c2)cc1 MWMXLLVOFFIXAS-JUERFOTFSA-N 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021073337A JP7262508B2 (ja) | 2015-04-29 | 2021-04-23 | 癌を治療するための方法 |
| JP2023009598A JP7696378B2 (ja) | 2015-04-29 | 2023-01-25 | 癌を治療するための方法 |
Applications Claiming Priority (27)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154699P | 2015-04-29 | 2015-04-29 | |
| US62/154,699 | 2015-04-29 | ||
| US201562155451P | 2015-04-30 | 2015-04-30 | |
| US62/155,451 | 2015-04-30 | ||
| US201562158469P | 2015-05-07 | 2015-05-07 | |
| US62/158,469 | 2015-05-07 | ||
| US201562192944P | 2015-07-15 | 2015-07-15 | |
| US201562192940P | 2015-07-15 | 2015-07-15 | |
| US62/192,940 | 2015-07-15 | ||
| US62/192,944 | 2015-07-15 | ||
| US201562252085P | 2015-11-06 | 2015-11-06 | |
| US62/252,085 | 2015-11-06 | ||
| US201562252916P | 2015-11-09 | 2015-11-09 | |
| US62/252,916 | 2015-11-09 | ||
| US201562265774P | 2015-12-10 | 2015-12-10 | |
| US201562265696P | 2015-12-10 | 2015-12-10 | |
| US201562265658P | 2015-12-10 | 2015-12-10 | |
| US201562265663P | 2015-12-10 | 2015-12-10 | |
| US62/265,658 | 2015-12-10 | ||
| US62/265,774 | 2015-12-10 | ||
| US62/265,696 | 2015-12-10 | ||
| US62/265,663 | 2015-12-10 | ||
| US201662323576P | 2016-04-15 | 2016-04-15 | |
| US201662323572P | 2016-04-15 | 2016-04-15 | |
| US62/323,576 | 2016-04-15 | ||
| US62/323,572 | 2016-04-15 | ||
| PCT/US2016/030317 WO2016176665A1 (en) | 2015-04-29 | 2016-04-29 | Methods of treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021073337A Division JP7262508B2 (ja) | 2015-04-29 | 2021-04-23 | 癌を治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514593A JP2018514593A (ja) | 2018-06-07 |
| JP2018514593A5 true JP2018514593A5 (cg-RX-API-DMAC7.html) | 2019-05-30 |
| JP6926065B2 JP6926065B2 (ja) | 2021-08-25 |
Family
ID=57198783
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509732A Active JP6926066B2 (ja) | 2015-04-29 | 2016-04-29 | 癌を治療するための方法 |
| JP2017556627A Active JP7019422B2 (ja) | 2015-04-29 | 2016-04-29 | 癌を治療するための方法 |
| JP2018509731A Active JP6926065B2 (ja) | 2015-04-29 | 2016-04-29 | 癌を治療するための方法 |
| JP2021052305A Active JP7146992B2 (ja) | 2015-04-29 | 2021-03-25 | 癌を治療するための方法 |
| JP2021073337A Active JP7262508B2 (ja) | 2015-04-29 | 2021-04-23 | 癌を治療するための方法 |
| JP2022150560A Active JP7516472B2 (ja) | 2015-04-29 | 2022-09-21 | 癌を治療するための方法 |
| JP2023009598A Active JP7696378B2 (ja) | 2015-04-29 | 2023-01-25 | 癌を治療するための方法 |
| JP2024107407A Active JP7745708B2 (ja) | 2015-04-29 | 2024-07-03 | 癌を治療するための方法 |
| JP2025153179A Pending JP2025170141A (ja) | 2015-04-29 | 2025-09-16 | 癌を治療するための方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509732A Active JP6926066B2 (ja) | 2015-04-29 | 2016-04-29 | 癌を治療するための方法 |
| JP2017556627A Active JP7019422B2 (ja) | 2015-04-29 | 2016-04-29 | 癌を治療するための方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021052305A Active JP7146992B2 (ja) | 2015-04-29 | 2021-03-25 | 癌を治療するための方法 |
| JP2021073337A Active JP7262508B2 (ja) | 2015-04-29 | 2021-04-23 | 癌を治療するための方法 |
| JP2022150560A Active JP7516472B2 (ja) | 2015-04-29 | 2022-09-21 | 癌を治療するための方法 |
| JP2023009598A Active JP7696378B2 (ja) | 2015-04-29 | 2023-01-25 | 癌を治療するための方法 |
| JP2024107407A Active JP7745708B2 (ja) | 2015-04-29 | 2024-07-03 | 癌を治療するための方法 |
| JP2025153179A Pending JP2025170141A (ja) | 2015-04-29 | 2025-09-16 | 癌を治療するための方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (12) | US20180153828A1 (cg-RX-API-DMAC7.html) |
| EP (4) | EP3288382A4 (cg-RX-API-DMAC7.html) |
| JP (9) | JP6926066B2 (cg-RX-API-DMAC7.html) |
| KR (9) | KR102682763B1 (cg-RX-API-DMAC7.html) |
| CN (5) | CN113750091B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2016256470B2 (cg-RX-API-DMAC7.html) |
| BR (3) | BR112017023228A2 (cg-RX-API-DMAC7.html) |
| CA (3) | CA2984200C (cg-RX-API-DMAC7.html) |
| HK (3) | HK1251409A1 (cg-RX-API-DMAC7.html) |
| IL (10) | IL255189B2 (cg-RX-API-DMAC7.html) |
| MX (6) | MX393599B (cg-RX-API-DMAC7.html) |
| RU (3) | RU2747228C2 (cg-RX-API-DMAC7.html) |
| SG (4) | SG11201708860SA (cg-RX-API-DMAC7.html) |
| WO (3) | WO2016176666A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| PL3122426T3 (pl) | 2014-03-28 | 2023-05-15 | Duke University | Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego |
| BR112017023228A2 (en) * | 2015-04-29 | 2018-11-06 | Radius Pharmaceuticals, Inc. | methods for cancer treatment |
| AR107616A1 (es) | 2016-02-15 | 2018-05-16 | Sanofi Sa | Compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CA3036568A1 (en) * | 2016-09-27 | 2018-04-05 | Radius Health, Inc. | Methods for treating ovarian cancer |
| NZ752443A (en) | 2016-10-11 | 2022-11-25 | Univ Duke | Lasofoxifene treatment of er+ breast cancer |
| SG11201903908PA (en) | 2016-11-17 | 2019-05-30 | Sanofi Sa | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof |
| EP3565542B1 (en) | 2017-01-05 | 2024-04-10 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
| EP3595725B1 (en) * | 2017-03-16 | 2023-05-03 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
| US12012421B2 (en) | 2017-07-07 | 2024-06-18 | Hoffmann-La Roche Inc. | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
| EP3434272A1 (en) * | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| US11179365B2 (en) | 2017-11-16 | 2021-11-23 | Novartis Ag | Pharmaceutical combination comprising LSZ102 and ribociclib |
| US12012420B2 (en) | 2017-11-21 | 2024-06-18 | Hoffmann-La Roche, Inc. | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
| US10695333B2 (en) | 2017-12-01 | 2020-06-30 | Novartis Ag | Pharmaceutical combination comprising LSZ102 and alpelisib |
| CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| CN110585429B (zh) * | 2018-06-12 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物治疗肿瘤疾病的用途 |
| SG11202013177WA (en) * | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals Inc | Polymorphic forms of rad 1901-2hcl |
| CN112638869B (zh) | 2018-09-07 | 2025-04-25 | 赛诺菲 | 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的盐及其制备方法 |
| MA54293A (fr) * | 2018-11-30 | 2021-10-06 | Radius Pharmaceuticals Inc | Élacestrant en combinaison avec de l'abemaciclib chez des femmes atteintes d'un cancer du sein |
| WO2020118213A1 (en) * | 2018-12-06 | 2020-06-11 | Radius Pharmaceuticals, Inc. | Methods for treating cancer resistant to cdk4/6 inhibitors |
| JP7497353B2 (ja) * | 2018-12-06 | 2024-06-10 | ラジウス ファーマシューティカルズ，インコーポレイテッド | Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法 |
| BR112021011222A2 (pt) * | 2018-12-12 | 2021-08-24 | Chemocentryx, Inc. | Inibidores de cxcr7 para o tratamento de câncer |
| MA54946A (fr) | 2019-02-12 | 2021-12-22 | Radius Pharmaceuticals Inc | Procédés et composés |
| JP2022531898A (ja) * | 2019-05-09 | 2022-07-12 | サノフイ | 転移性または進行性乳房がん患者において使用するための６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸 |
| AU2020311337A1 (en) | 2019-07-07 | 2022-01-20 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
| KR102341347B1 (ko) * | 2019-11-28 | 2021-12-20 | 의료법인 성광의료재단 | 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법 |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| JP7708772B2 (ja) * | 2020-03-06 | 2025-07-15 | オレマ ファーマシューティカルズ インク． | エストロゲン受容体関連疾患の治療方法 |
| CA3179907A1 (en) * | 2020-04-24 | 2021-10-28 | Astrazeneca Ab | Dosage regimen for the treatment of cancer |
| JP2023500558A (ja) | 2020-05-12 | 2023-01-10 | ジェネンテック， インコーポレイテッド | Ｇｄｃ－９５４５及びｃｄｋ４／６阻害剤を含む併用療法を使用した乳がん治療 |
| MX2023001572A (es) * | 2020-08-05 | 2023-05-08 | Aizant Drug Res Solutions Private Limited | Formas farmaceuticas sólidas de palbociclib. |
| US20220193072A1 (en) * | 2020-12-14 | 2022-06-23 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degrader |
| JP2024506348A (ja) * | 2021-02-16 | 2024-02-13 | ジェネンテック， インコーポレイテッド | Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療 |
| CN113662942B (zh) * | 2021-08-19 | 2023-02-07 | 中国人民解放军陆军军医大学第一附属医院 | 药物组合物及其在smo突变性髓母细胞瘤中的应用 |
| WO2023064519A1 (en) | 2021-10-14 | 2023-04-20 | Teva Pharmaceuticals International Gmbh | Solid state forms of elacestrant and processes for preparation thereof |
| DE102021130035A1 (de) | 2021-11-17 | 2023-05-17 | USound GmbH | MEMS-Schallwandler mit einer gekrümmten Kontur eines Kragarmelements |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| WO2024104268A1 (zh) * | 2022-11-15 | 2024-05-23 | 苏州科睿思制药有限公司 | 艾拉司群二盐酸盐的共晶及其制备方法和用途 |
| KR20240105964A (ko) * | 2022-12-29 | 2024-07-08 | 주식회사 삼양홀딩스 | 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법 |
| EP4574811A1 (en) | 2023-12-22 | 2025-06-25 | Sandoz Ag | Crystalline forms of elacestrant dihydrochloride |
| WO2025158416A1 (en) | 2024-01-25 | 2025-07-31 | Assia Chemical Industries Ltd. | Solid state forms of elacestrant and processes for preparation thereof |
Family Cites Families (160)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3939346A1 (de) | 1989-11-29 | 1991-06-06 | Behringwerke Ag | Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide |
| US5589452A (en) | 1992-07-14 | 1996-12-31 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
| US5977070A (en) | 1992-07-14 | 1999-11-02 | Piazza; Christin Teresa | Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
| US5821225A (en) | 1992-07-14 | 1998-10-13 | Syntex (U.S.A.) Inc. | Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp |
| DE19517430A1 (de) | 1995-05-12 | 1996-11-14 | Boehringer Mannheim Gmbh | Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode |
| IT1285405B1 (it) | 1995-06-06 | 1998-06-03 | Alza Corp | Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto. |
| US5955574A (en) | 1995-07-13 | 1999-09-21 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. | Analogs of parathyroid hormone |
| US5723577A (en) | 1995-07-13 | 1998-03-03 | Biomeasure Inc. | Analogs of parathyroid hormone |
| US7410948B2 (en) | 1995-07-13 | 2008-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Analogs of parathyroid hormone |
| US6544949B1 (en) | 1995-07-13 | 2003-04-08 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Analogs of parathyroid hormone |
| US5969095A (en) | 1995-07-13 | 1999-10-19 | Biomeasure, Inc. | Analogs of parathyroid hormone |
| DE19538687A1 (de) | 1995-10-17 | 1997-04-24 | Boehringer Mannheim Gmbh | Stabile pharmazeutische Darreichungsformen enthaltend Parathormon |
| DE19539574A1 (de) | 1995-10-25 | 1997-04-30 | Boehringer Mannheim Gmbh | Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren |
| TW518219B (en) | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| TW505654B (en) | 1996-07-30 | 2002-10-11 | Hoffmann La Roche | Synthesis of analogs of PTH and PTHrP |
| US6017729A (en) | 1996-12-23 | 2000-01-25 | Immunex Corporation | Receptor activator of NF-κB |
| US6136784A (en) | 1997-01-08 | 2000-10-24 | Amylin Pharmaceuticals, Inc. | Amylin agonist pharmaceutical compositions containing insulin |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| WO1999012561A2 (en) | 1997-09-09 | 1999-03-18 | F. Hoffman-La Roche Ag | FRACTURE HEALING USING PTHrP ANALOGS |
| ZA9811127B (en) | 1997-12-09 | 2000-07-11 | Lilly Co Eli | Stabilized teriparatide solutions. |
| US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
| AU757192B2 (en) | 1997-12-11 | 2003-02-06 | Alza Corporation | Device for enhancing transdermal agent flux |
| AU739616B2 (en) | 1997-12-11 | 2001-10-18 | Alza Corporation | Device for enhancing transdermal agent flux |
| EP0922467A3 (en) | 1997-12-12 | 2000-05-24 | Takeda Chemical Industries, Ltd. | Iontophoretic drug delivery |
| JP4154017B2 (ja) | 1997-12-30 | 2008-09-24 | 久光製薬株式会社 | イオントフォレーシス装置および薬物ユニット |
| US6091975A (en) | 1998-04-01 | 2000-07-18 | Alza Corporation | Minimally invasive detecting device |
| SE9801495D0 (sv) | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulationa |
| US6316410B1 (en) | 1999-09-22 | 2001-11-13 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
| WO2001036039A2 (en) | 1999-11-17 | 2001-05-25 | Novartis Ag | Iontophoretic transdermal delivery of peptides |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| US20010044431A1 (en) | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| US20050124537A1 (en) | 2000-04-27 | 2005-06-09 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| EP1307232B1 (en) | 2000-08-03 | 2007-03-07 | Antares Pharma IPL AG | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| EP1313700B1 (en) | 2000-08-23 | 2005-11-09 | Akzo Nobel N.V. | 10-aryl-11h-benzo[b]fluorene derivatives and analogs as estrogenic compounds |
| US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| WO2002094368A1 (en) | 2000-10-26 | 2002-11-28 | Alza Corporation | Transdermal drug delivery devices having coated microprotrusions |
| MXPA03009603A (es) | 2001-04-20 | 2004-12-06 | Johnson & Johnson | Arreglo de microproyeccion que tiene un agente benefico que contiene un recubrimiento. |
| NO345566B1 (no) | 2001-06-26 | 2021-04-19 | Amgen Inc | OPGL bindende antistoff, farmasøytisk sammensetning samt anvendelse derav |
| US6881203B2 (en) | 2001-09-05 | 2005-04-19 | 3M Innovative Properties Company | Microneedle arrays and methods of manufacturing the same |
| US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
| ES2297056T3 (es) | 2001-12-20 | 2008-05-01 | Alza Corporation | Micro-proyecciones para perforacion de la piel que tienen control de la profundidad de perforacion. |
| JP2005524630A (ja) | 2002-01-14 | 2005-08-18 | ノルディック・ビオサイエンス・エー／エス | エストロゲン受容体を介する軟骨破壊の抑制 |
| AU2003219787A1 (en) | 2002-02-14 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Formulation strategies in stabilizing peptides in organic solvents and in dried states |
| EP1513547A4 (en) | 2002-05-23 | 2009-11-04 | Michael F Holick | USE OF PEPTIDE ANALOGUES OF PARATHYROID HORMONE FOR THE TREATMENT OF VAGINAL ATROPHY |
| TW200307553A (en) | 2002-05-24 | 2003-12-16 | Akzo Nobel Nv | Treatment of post-menopausal complaints in breast cancer patients |
| WO2003105772A2 (en) | 2002-06-13 | 2003-12-24 | Beth Israel Deaconess Medical Center, Inc. | Analogs of parathyroid hormone and pth-related protein as bone anabolic agents |
| WO2004007520A2 (en) | 2002-07-12 | 2004-01-22 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
| MXPA05000597A (es) | 2002-07-19 | 2005-04-28 | 3M Innovative Properties Co | Dispositivos de microaguja y aparatos de administracion por microaguja. |
| WO2004035624A2 (en) | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
| JP2006517389A (ja) | 2002-10-14 | 2006-07-27 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ−２化合物、製剤、及びそれらの使用 |
| US8133505B2 (en) | 2002-10-31 | 2012-03-13 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| US7662404B2 (en) | 2002-10-31 | 2010-02-16 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides |
| US7383084B2 (en) | 2002-10-31 | 2008-06-03 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| IL152574A (en) | 2002-10-31 | 2009-09-22 | Transpharma Medical Ltd | A system for passing through the skin of dry items or dried medicines |
| CA2511966A1 (en) | 2002-11-01 | 2004-07-22 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| JP4500689B2 (ja) * | 2002-12-26 | 2010-07-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的エストロゲン受容体モジュレーター |
| JP2007505164A (ja) | 2003-06-10 | 2007-03-08 | スミスクライン ビーチャム コーポレーション | アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての１−アミノナフタレン類 |
| WO2005000795A2 (en) | 2003-06-10 | 2005-01-06 | Smithkline Beecham Corporation | Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| TW200518771A (en) | 2003-06-30 | 2005-06-16 | Alza Corp | Formulations for coated microprojections containing non-volatile counterions |
| EP1638468B1 (en) | 2003-06-30 | 2007-08-15 | Alza Corporation | Method for coating skin piercing microprojections |
| WO2005014034A1 (en) | 2003-07-14 | 2005-02-17 | Nps Allelix Corp. | Stabilized formulation of parathyroid hormone |
| US7141544B2 (en) | 2003-10-10 | 2006-11-28 | Baxter International, Inc. | Stabilization of pharmaceutical protein formulations with small peptides |
| US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
| CA2543280A1 (en) | 2003-10-28 | 2005-05-19 | Alza Corporation | Delivery of polymer conjugates of therapeutic peptides and proteins via coated microporjections |
| WO2005044333A2 (en) | 2003-10-31 | 2005-05-19 | Alza Corporation | Self-actuating applicator for microprojection array |
| CN100548228C (zh) | 2003-11-13 | 2009-10-14 | 阿尔扎公司 | 用于透皮递送的组合物和装置 |
| EP1687274A1 (en) | 2003-11-20 | 2006-08-09 | Warner-Lambert Company LLC | Androgen receptor modulators |
| BRPI0416822A (pt) | 2003-11-21 | 2007-03-06 | Alza Corp | método e sistema de liberação de vacina transdérmica com ultra-som |
| IL159273A0 (en) | 2003-12-09 | 2004-06-01 | Transpharma Medical Ltd | Transdermal delivery system for sustained release of polypeptides |
| US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
| RU2397176C2 (ru) | 2004-01-07 | 2010-08-20 | Эндорешерш, Инк. | Стероидные фармацевтические продукты, направленные на спираль 12 |
| IL160033A0 (en) | 2004-01-25 | 2004-06-20 | Transpharma Medical Ltd | Transdermal delivery system for polynucleotides |
| TWI359026B (en) | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
| GB0405033D0 (en) | 2004-03-05 | 2004-04-07 | Karobio Ab | Novel pharmaceutical compositions |
| US20080125399A1 (en) | 2004-04-08 | 2008-05-29 | Jiabing Wang | 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators |
| WO2005115441A2 (en) | 2004-05-10 | 2005-12-08 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
| EP1747193A1 (en) | 2004-05-11 | 2007-01-31 | Pfizer Products Incorporated | Benzonitrile derivatives to treat musculoskeletal frailty |
| CA2566032A1 (en) | 2004-05-13 | 2005-12-01 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents |
| WO2005113008A1 (en) | 2004-05-21 | 2005-12-01 | Mediplex Corp. | Delivery agents for enhancing mucosal absorption of therapeutic agents |
| US7906137B2 (en) | 2004-05-21 | 2011-03-15 | Mediplex Corporation, Korea | Delivery agents for enhancing mucosal absorption of therapeutic agents |
| US20090069226A1 (en) | 2004-05-28 | 2009-03-12 | Amylin Pharmaceuticals, Inc. | Transmucosal delivery of peptides and proteins |
| TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| AU2005310238A1 (en) | 2004-10-29 | 2006-06-08 | Merck Sharp & Dohme Corp. | N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators |
| CA2588080C (en) | 2004-11-18 | 2013-01-08 | 3M Innovative Properties Company | Masking method for coating a microneedle array |
| US8057842B2 (en) | 2004-11-18 | 2011-11-15 | 3M Innovative Properties Company | Method of contact coating a microneedle array |
| WO2006054299A2 (en) | 2004-11-18 | 2006-05-26 | Transpharma Medical Ltd. | Combined micro-channel generation and iontophoresis for transdermal delivery of pharmaceutical agents |
| CA2593112A1 (en) | 2005-01-21 | 2006-07-27 | Alza Corporation | Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion |
| WO2006113552A2 (en) | 2005-04-15 | 2006-10-26 | Smithkline Beecham Corporation | Cyanoarylamines |
| KR100700869B1 (ko) | 2005-06-03 | 2007-03-29 | 재단법인 목암생명공학연구소 | Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물 |
| JP2008546643A (ja) | 2005-06-06 | 2008-12-25 | スミスクライン ビーチャム コーポレーション | ４−置換アリールアミン誘導体および医薬組成物におけるその使用 |
| WO2007005887A2 (en) | 2005-07-01 | 2007-01-11 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds, compositions and uses thereof |
| US20070021216A1 (en) | 2005-07-19 | 2007-01-25 | Sony Ericsson Mobile Communications Ab | Seamless gaming method and apparatus |
| JP2008303145A (ja) | 2005-09-22 | 2008-12-18 | Takeda Chem Ind Ltd | Ｇｒｋ阻害剤からなる強心薬 |
| CA2629193C (en) | 2005-11-18 | 2016-03-29 | 3M Innovative Properties Company | Coatable compositions, coatings derived therefrom and microarrays having such coatings |
| JP2009522288A (ja) | 2005-12-28 | 2009-06-11 | アルザ コーポレイション | 安定な治療剤形 |
| WO2007106597A2 (en) | 2006-03-15 | 2007-09-20 | Alza Corporation | Method for the transdermal delivery of parathyroid hormone agents for treating osteopenia |
| WO2007124409A2 (en) | 2006-04-20 | 2007-11-01 | Velocys, Inc. | Process for treating and/or forming a non-newtonian fluid using microchannel process technology |
| WO2007124411A1 (en) | 2006-04-20 | 2007-11-01 | 3M Innovative Properties Company | Device for applying a microneedle array |
| US8779004B2 (en) | 2006-04-20 | 2014-07-15 | Amgen, Inc. | Stable emulsion formulations |
| CN101085743B (zh) | 2006-06-06 | 2012-02-15 | 浙江大德药业集团有限公司 | 含氟烷氧基康普立停衍生物及制法和用途 |
| US8933130B2 (en) | 2006-06-23 | 2015-01-13 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
| MX2009000385A (es) | 2006-07-12 | 2009-04-06 | Univ Tennessee Res Foundation | Acil-anilidas sustituidas y metodos de uso de las mismas. |
| KR101202240B1 (ko) | 2006-08-24 | 2012-11-16 | 유니버시티 오브 테네시 리서치 파운데이션 | 치환된 아실아닐리드 및 그의 사용 방법 |
| EA015644B1 (ru) | 2006-08-25 | 2011-10-31 | Арес Трейдинг С.А. | Способ лечения заболеваний хряща |
| CN1927815A (zh) | 2006-09-25 | 2007-03-14 | 天津理工大学 | 邻苄胺基苯基醚化合物、化合物的衍生物及其制备方法与用途 |
| ES2739459T3 (es) | 2006-10-03 | 2020-01-31 | Radius Health Inc | Una composición estable que comprende una proteína anabólica ósea, es decir un análogo de PTHrP y usos de la misma |
| US7803770B2 (en) | 2006-10-03 | 2010-09-28 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
| WO2008044033A1 (en) | 2006-10-11 | 2008-04-17 | Astrazeneca Ab | Amide derivatives |
| US20100030100A1 (en) | 2007-02-06 | 2010-02-04 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle Device For Diagnosis Of Allergy |
| WO2008121602A1 (en) | 2007-03-29 | 2008-10-09 | Smithkline Beecham Corporation | Chemical compounds |
| WO2008124000A2 (en) | 2007-04-02 | 2008-10-16 | Ligand Pharmaceuticals Incorporated | Thiazole derivatives as androgen receptor modulator compounds |
| AU2008241470B2 (en) | 2007-04-16 | 2013-11-07 | Corium Pharma Solutions, Inc. | Solvent-cast microneedle arrays containing active |
| GB0707938D0 (en) | 2007-04-25 | 2007-05-30 | Univ Strathclyde | Precipitation stabilising compositions |
| JP5350369B2 (ja) | 2007-05-31 | 2013-11-27 | ダコ デンマーク アクティーゼルスカブ | 乳癌治療および予後におけるｅｓｒコピー数変化の利用方法 |
| CA2690556A1 (en) | 2007-06-12 | 2008-12-24 | Schering Corporation | Histone h2ax (hh2ax) biomarker for fti sensitivity |
| EP2155226A4 (en) | 2007-06-14 | 2010-07-28 | Univ California | COMPOUNDS FOR INHIBITING THE PROTEIN AGGREGATION AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US20120150023A1 (en) | 2007-08-06 | 2012-06-14 | Kaspar Roger L | Microneedle arrays for active agent delivery |
| DK2205169T3 (da) | 2007-09-28 | 2017-02-20 | The Queen's Univ Of Belfast | Anordning og fremgangsmåde til fremføring |
| WO2009054988A1 (en) | 2007-10-23 | 2009-04-30 | Alza Corporation | Transdermal sustained release drug delivery |
| EP2052736A1 (en) | 2007-10-26 | 2009-04-29 | Nycomed Danmark ApS | Parathyroid hormone formulations und uses thereof |
| US8642532B2 (en) | 2007-11-16 | 2014-02-04 | Guohan Yang | Excipients for protein stabilization |
| WO2009133861A1 (ja) | 2008-04-28 | 2009-11-05 | 武田薬品工業株式会社 | 環状アミン化合物 |
| WO2009137104A1 (en) * | 2008-05-09 | 2009-11-12 | Radius Health, Inc. | Combination therapy for breastcancer comprising an antiestrogenic agent |
| WO2010022176A1 (en) | 2008-08-19 | 2010-02-25 | Ferring International Center S.A. | Methods of treatment for skeletal conditons |
| EP2349200A1 (en) | 2008-10-15 | 2011-08-03 | Intarcia Therapeutics, Inc | Highly concentrated drug particles, formulations, suspensions and uses thereof |
| BRPI0920973B8 (pt) | 2008-11-04 | 2021-05-25 | Aska Pharm Co Ltd | composição aquosa contendo hormônio estimulanete de folículos |
| EP2355887B1 (en) | 2008-11-18 | 2017-08-02 | 3M Innovative Properties Company | Hollow microneedle array |
| KR101634836B1 (ko) | 2008-12-26 | 2016-06-29 | 히사미쓰 세이야꾸 가부시키가이샤 | 마이크로 니들 디바이스 |
| US20100203014A1 (en) | 2009-02-04 | 2010-08-12 | Aegis Therapeutics Llc | Zwitterionic buffered acidic peptide and protein formulations |
| US20100226966A1 (en) | 2009-03-03 | 2010-09-09 | Daddona Peter E | Method for transdermal controlled release drug delivery |
| WO2010118287A1 (en) | 2009-04-10 | 2010-10-14 | Radius Health, Inc. | Selective androgen receptor modulators |
| JP5820805B2 (ja) | 2009-04-24 | 2015-11-24 | コリウム インターナショナル， インコーポレイテッド | マイクロプロジェクションのアレイの製造のためのプロセス |
| CN102497909B (zh) | 2009-07-31 | 2014-10-29 | 3M创新有限公司 | 中空微针阵列 |
| US20120219538A1 (en) | 2009-11-02 | 2012-08-30 | Therapeomic Ag | Stabilized protein formulations and use thereof |
| US20110172609A1 (en) | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Microneedle component assembly for drug delivery device |
| CN101912600B (zh) | 2010-01-11 | 2014-01-29 | 杨国汉 | 改善胰岛素在溶液中稳定性的方法 |
| IE20100174A1 (en) | 2010-03-25 | 2012-02-29 | Trinity College Dublin | Transdermal administration of peptides |
| ES2719595T3 (es) | 2010-05-04 | 2019-07-11 | Corium Int Inc | Método y dispositivo para la administración transdérmica de la hormona paratiroidea usando una matriz de microproyección |
| US9693950B2 (en) | 2010-05-28 | 2017-07-04 | 3M Innovative Properties Company | Aqueous formulations for coating microneedle arrays |
| EP2582371B1 (en) * | 2010-06-16 | 2019-10-16 | Endorecherche, Inc. | Methods of treating or preventing estrogen-related diseases |
| WO2012075375A1 (en) | 2010-12-02 | 2012-06-07 | Lanco Biosciences, Inc. | Delivery of parathyroid hormones by microinjection systems |
| JP2014508765A (ja) | 2011-03-01 | 2014-04-10 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 副甲状腺ホルモン類似体、組成物およびその使用 |
| CA2833571A1 (en) | 2011-04-22 | 2012-10-26 | Radius Health, Inc. | Method of drug delivery for pth, pthrp and related peptides |
| CA2857502C (en) | 2011-11-30 | 2019-08-13 | 3M Innovative Properties Company | Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same |
| GB201217439D0 (en) | 2012-09-28 | 2012-11-14 | Topotarget As | Combination therapy |
| CN105451735B (zh) | 2013-06-19 | 2019-01-11 | 西拉根制药公司 | 氮杂环丁烷雌激素受体调节剂和其用途 |
| WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
| CN104436194B (zh) | 2013-09-18 | 2018-03-30 | 北京大学 | 具有协同增效作用的抗癌组合物 |
| EP3099305B1 (en) * | 2014-01-27 | 2025-11-19 | Dna Seq 2, Inc. | Methods and systems for determination of an effective therapeutic regimen and drug discovery |
| WO2015136016A2 (en) | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| PL3122426T3 (pl) * | 2014-03-28 | 2023-05-15 | Duke University | Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego |
| WO2015160986A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016097071A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
| AR104068A1 (es) * | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
| BR112017023228A2 (en) | 2015-04-29 | 2018-11-06 | Radius Pharmaceuticals, Inc. | methods for cancer treatment |
-
2016
- 2016-04-29 BR BR112017023228-6A patent/BR112017023228A2/en not_active Application Discontinuation
- 2016-04-29 CA CA2984200A patent/CA2984200C/en active Active
- 2016-04-29 CN CN202110933929.XA patent/CN113750091B/zh active Active
- 2016-04-29 CN CN201680038907.4A patent/CN108024540B/zh active Active
- 2016-04-29 EP EP16787289.4A patent/EP3288382A4/en active Pending
- 2016-04-29 JP JP2018509732A patent/JP6926066B2/ja active Active
- 2016-04-29 AU AU2016256470A patent/AU2016256470B2/en active Active
- 2016-04-29 KR KR1020177034606A patent/KR102682763B1/ko active Active
- 2016-04-29 MX MX2021005561A patent/MX393599B/es unknown
- 2016-04-29 SG SG11201708860SA patent/SG11201708860SA/en unknown
- 2016-04-29 IL IL255189A patent/IL255189B2/en unknown
- 2016-04-29 AU AU2016256471A patent/AU2016256471B2/en active Active
- 2016-04-29 HK HK18110957.0A patent/HK1251409A1/zh unknown
- 2016-04-29 IL IL255148A patent/IL255148B2/en unknown
- 2016-04-29 EP EP16787291.0A patent/EP3288383A4/en active Pending
- 2016-04-29 SG SG11201708858WA patent/SG11201708858WA/en unknown
- 2016-04-29 BR BR112017023233-2A patent/BR112017023233A2/en not_active Application Discontinuation
- 2016-04-29 WO PCT/US2016/030321 patent/WO2016176666A1/en not_active Ceased
- 2016-04-29 MX MX2017013794A patent/MX394676B/es unknown
- 2016-04-29 IL IL297369A patent/IL297369B2/en unknown
- 2016-04-29 MX MX2017013801A patent/MX384908B/es unknown
- 2016-04-29 IL IL319266A patent/IL319266A/en unknown
- 2016-04-29 SG SG11201708861VA patent/SG11201708861VA/en unknown
- 2016-04-29 SG SG10202104177VA patent/SG10202104177VA/en unknown
- 2016-04-29 CN CN202110579478.4A patent/CN113288887A/zh active Pending
- 2016-04-29 IL IL255261A patent/IL255261B2/en unknown
- 2016-04-29 RU RU2017140675A patent/RU2747228C2/ru active
- 2016-04-29 AU AU2016256469A patent/AU2016256469B2/en active Active
- 2016-04-29 JP JP2017556627A patent/JP7019422B2/ja active Active
- 2016-04-29 EP EP22155988.3A patent/EP4039253A1/en active Pending
- 2016-04-29 KR KR1020257033320A patent/KR20250153309A/ko active Pending
- 2016-04-29 IL IL310069A patent/IL310069B2/en unknown
- 2016-04-29 WO PCT/US2016/030316 patent/WO2016176664A1/en not_active Ceased
- 2016-04-29 KR KR1020177034603A patent/KR102676629B1/ko active Active
- 2016-04-29 KR KR1020247019929A patent/KR102871380B1/ko active Active
- 2016-04-29 RU RU2017140674A patent/RU2737496C2/ru active
- 2016-04-29 BR BR112017023269-3A patent/BR112017023269A2/en not_active Application Discontinuation
- 2016-04-29 KR KR1020257033321A patent/KR20250152679A/ko active Pending
- 2016-04-29 MX MX2017013802A patent/MX384605B/es unknown
- 2016-04-29 HK HK18110955.2A patent/HK1251407A1/zh unknown
- 2016-04-29 RU RU2017140676A patent/RU2745678C2/ru active
- 2016-04-29 KR KR1020257033319A patent/KR20250152678A/ko active Pending
- 2016-04-29 EP EP16787290.2A patent/EP3294065A4/en active Pending
- 2016-04-29 KR KR1020247019989A patent/KR102871408B1/ko active Active
- 2016-04-29 CN CN201680038908.9A patent/CN108135177B/zh active Active
- 2016-04-29 KR KR1020177034608A patent/KR102676705B1/ko active Active
- 2016-04-29 CA CA2984357A patent/CA2984357A1/en active Pending
- 2016-04-29 KR KR1020247022060A patent/KR102871388B1/ko active Active
- 2016-04-29 JP JP2018509731A patent/JP6926065B2/ja active Active
- 2016-04-29 HK HK18110956.1A patent/HK1251408A1/zh unknown
- 2016-04-29 CA CA2984195A patent/CA2984195C/en active Active
- 2016-04-29 WO PCT/US2016/030317 patent/WO2016176665A1/en not_active Ceased
- 2016-04-29 CN CN201680039059.9A patent/CN108024541B/zh active Active
-
2017
- 2017-10-26 MX MX2021003389A patent/MX2021003389A/es unknown
- 2017-10-26 US US15/794,774 patent/US20180153828A1/en not_active Abandoned
- 2017-10-26 MX MX2021004881A patent/MX2021004881A/es unknown
- 2017-10-26 US US15/794,861 patent/US20180169101A1/en not_active Abandoned
- 2017-10-26 US US15/794,910 patent/US20180214393A1/en not_active Abandoned
-
2019
- 2019-08-20 US US16/545,859 patent/US20200046655A1/en not_active Abandoned
- 2019-09-24 US US16/580,914 patent/US11413258B2/en active Active
-
2020
- 2020-08-04 US US16/985,021 patent/US11819480B2/en active Active
-
2021
- 2021-03-25 JP JP2021052305A patent/JP7146992B2/ja active Active
- 2021-04-23 JP JP2021073337A patent/JP7262508B2/ja active Active
- 2021-10-25 US US17/510,050 patent/US12263141B2/en active Active
-
2022
- 2022-06-29 US US17/852,673 patent/US20220339126A1/en active Pending
- 2022-09-21 JP JP2022150560A patent/JP7516472B2/ja active Active
-
2023
- 2023-01-25 JP JP2023009598A patent/JP7696378B2/ja active Active
- 2023-09-12 US US18/367,103 patent/US20240099996A1/en not_active Abandoned
- 2023-10-24 IL IL307981A patent/IL307981B1/en unknown
- 2023-10-24 IL IL307983A patent/IL307983B1/en unknown
- 2023-11-16 US US18/511,036 patent/US20240091177A1/en not_active Abandoned
-
2024
- 2024-07-03 JP JP2024107407A patent/JP7745708B2/ja active Active
-
2025
- 2025-08-12 US US19/297,614 patent/US20250367140A1/en active Pending
- 2025-08-18 US US19/302,585 patent/US20250367141A1/en active Pending
- 2025-09-16 JP JP2025153179A patent/JP2025170141A/ja active Pending
- 2025-10-13 IL IL323924A patent/IL323924A/en unknown
- 2025-10-13 IL IL323926A patent/IL323926A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514593A5 (cg-RX-API-DMAC7.html) | ||
| RU2017140674A (ru) | Способы лечения рака | |
| JP2018530549A5 (cg-RX-API-DMAC7.html) | ||
| US9675586B2 (en) | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer | |
| JP2017518291A5 (cg-RX-API-DMAC7.html) | ||
| JP2018140982A5 (cg-RX-API-DMAC7.html) | ||
| JP2011518883A5 (cg-RX-API-DMAC7.html) | ||
| JP2018518529A5 (cg-RX-API-DMAC7.html) | ||
| JP2019529581A5 (cg-RX-API-DMAC7.html) | ||
| JP2020511467A5 (cg-RX-API-DMAC7.html) | ||
| JP2020514292A5 (cg-RX-API-DMAC7.html) | ||
| JP2017518292A5 (cg-RX-API-DMAC7.html) | ||
| RU2017116070A (ru) | Способ лечения первичного гормонорезистентного эндометриального рака и рака груди | |
| JP2013500324A5 (cg-RX-API-DMAC7.html) | ||
| JP2013544892A5 (cg-RX-API-DMAC7.html) | ||
| CN107249587B (zh) | 用于治疗乳腺癌的抗组胺药 | |
| TWI234458B (en) | Inhibition of the growth factor dependency of tumor cells | |
| JP2019501957A5 (cg-RX-API-DMAC7.html) | ||
| EP3654967A1 (en) | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer | |
| JP2015535282A5 (cg-RX-API-DMAC7.html) | ||
| Gultekin et al. | Unusual presentation of an adenocarcinoma of the lung metastasizing to the mandible, including molecular analysis and a review of the literature | |
| Prol et al. | Oral and maxillary metastases: retrospective clinical analysis of 21 cases | |
| AU2004243500A1 (en) | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases | |
| JP2007510661A5 (cg-RX-API-DMAC7.html) | ||
| US20080261929A1 (en) | Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases |